RSV
-
a vaccine with blockbuster potential

 

RSV is a respiratory pathogen which infects patients of all ages. The infection can be especially severe in infants and older adults with chronic pulmonary or cardiovascular disease. Each year the virus infects 64 million people and is responsible for 160,000 deaths worldwide. Currently, there is no vaccine available for this highly contagious virus.
 

Target population and market size

Mymetics RSV vaccine candidate is targeting the elderly population, representing a target population in the Western world of about 150 million. The potential RSV vaccine sales is estimated between USD 1. 2 and USD 1.5 billion USD a year and is thereby one of the few remaining vaccines with block-buster potential.

Mymetics’ RSV vaccine approach

The virosome is produced from the RSV virus, by dissolving the RSV membrane, taking out the genetic material and reconstituting the lipid membrane including the natural RSV proteins.

Encouraging results

In pre-clinical studies Mymetics’ vaccine has shown strong safety and immunogenicity and the vaccine did not induce enhanced disease, while mice and cotton rats were completely protected against a live virus challenge.

Partnering

On January 6, 2014 Mymetics announced a license and collaboration agreement to further develop Mymetics' RSV vaccine candidate with RSV Corporation (RSVC), a development company dedicated to the clinical development of the Mymetics RSV vaccine and funded by Astellas Pharma. On January 29th, 2016 Mymetics announced the discontinuation of the collaboration with RSVC, which will officially terminate on July 25th, 2016.

Mymetics has received $5 million as an upfront cash payment and was compensated for the Research and Development of the RSV vaccine during the years 2014 and 2015, thereby significantly strengthening its know-how and expertise in the RSV vaccine manufacturing, analytics and composition.

Mymetics is now evaluating the next steps for its RSV virosome vaccine candidate.